ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Pharmacological evaluation of a novel skeleton compound isobavachin (4?,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity

Zhao, Zean; Luo, Jian; Liao, Hui; Zheng, Fengxin; Chen, Xinhua; Luo, Jiajun; Chen, Yongjun; Zhao, Kunlu; Zhang, Shuqin; Tian, Jinhong; Wu, Ting; Li, Yongmei; Li, Lu; Yang, Yang; Lin, Cuiting; Zhang, Qun*; Tian, Yuanxin*; Pang, Jianxin*南方医科大学
Bioorganic Chemistry2023-4DOI: 10.1016/j.bioorg.2023.106405
2被引7阅读
引用收藏
分享

摘要

Previously we discovered a novel natural scaffold compound, isobavachin (4 ', 7-dihydroxy-8-prenylflavanone), as a potent URAT1 inhibitor by shape and structure based on a virtue screening approach. In this study, further urate-lowering mechanism, pharmacokinetics and toxicities of isobavachin were conducted. Isobavachin inhibited URAT1 with an IC50 value of 0.24 +/- 0.06 mu M, and residues S35, F365, I481 and R477 of URAT1 contributed to high affinity for isobavachin. Isobavachin also inhibited glucose transporter 9 (GLUT9), another pivotal urate reabsorption transporter, with an IC50 value of 1.12 +/- 0.26 mu M. Molecular docking and MMGBSA results indicated that isobavachin might compete residues R171, L75 and N333 with uric acid, which leads to inhibition of uric acid transport of GLUT9. Isobavachin weakly inhibited urate secretion transporters OAT1 with an IC50 value of 4.38 +/- 1.27 mu M, OAT3 with an IC50 of 3.64 +/- 0.62 mu M, and ABCG2 with an IC50 of 10.45 +/- 2.17 mu M. Isobavachin also inhibited xanthine oxidase (XOD) activity in vitro with an IC50 value of 14.43 +/- 3.56 mu M, and inhibited the hepatic XOD activities at 5-20 mg/kg in vivo. Docking and MMGBSA analysis indicated that isobavachin might bind to the Mo-Pt catalyze center of XOD, which leads to inhibition of uric acid production. In vivo, isobavachin exhibited powerful urate-lowering and uricosuric effects at 5-20 mg/kg compared with the positive drugs morin (20 mg/kg) and RDEA3170 (10 mg/kg). Safety assessments revealed that isobavachin was safe and had no obvious toxicities. Isobavachin has little cell toxicity in HK2 cells as indicated by the MTT assay. In vivo, after treatment with 50 mg/kg isobavachin for 14 days, isobavachin had little renal toxicity, as revealed by serum CR/BUN levels, and no hepatotoxicity as revealed by ALT/AST levels. Further HE examination also suggests that isobavachin has no obvious kidney/liver damage. A pharmacokinetic study in SD rats indicated isobavachin had lower bioavailability (12.84 +/- 5.13 %) but long half-time (7.04 +/- 2.68 h) to maintain a continuous plasma concentration. Collectively, these results indicate that isobavachin deserves further investi-gation as a candidate anti-hyperuricemic drug with a novel mechanism of action: selective urate reabsorption inhibitor (URAT1/GLUT9) with a moderate inhibitory effect on XOD.

学科与关键词

关键词
IsobavachinXODHyperuricemiaGoutURAT1GLUT9
相关
加载中…
  • Novel natural scaffold as hURAT1 inhibitor identified by 3D-shape-based, docking-based virtual screening approach and biological evaluation
    Chen, Xinhua; Zhao, Zean; Luo, Jiajun; Wu, Ting; Shen, Yudong; Chang, Shan; Wan, Shanhe; Li, Zhonghuang; Zhang, Jiajie*; Pang, Jianxin*; Tian, Yuanxin*Bioorganic Chemistry, 2021, 117: 105444.被引 6
  • Mechanism of anti-hyperuricemia of isobavachin based on network pharmacology and molecular docking
    Luo, Jia-jun; Chen, Xin-hua; Liang, Peng-ying; Zhao, Zean; Wu, Ting; Li, Zhong-huang; Wan, Shan-he; Luo, Jian; Pang, Jian-xin*; Zhang, Jia-jie*; Tian, Yuan-xin*Computers in Biology and Medicine, 2023, 155: 106637.
  • Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase
    Chen, Yanyu; Zhao, Zean; Li, Yongmei; Yang, Yang; Li, Lu; Jiang, Yu; Lin, Cuiting; Cao, Ying; Zhou, Pingzheng; Tian, Yuanxin; Wu, Ting*; Pang, Jianxin*PHYTOMEDICINE, 2021, 80: 153374.被引 46
查看全部 →

发表信息

论文状态
公开发表
期刊
Bioorganic Chemistry
发表日期
2023-04
卷期
第 133 卷
页码
106405
DOI
10.1016/j.bioorg.2023.106405
语言
ENGLISH
成果收录
SCIE
资助标注
National Science Foundation of China [81974507]

作者

  • Z

    Zhao, Zean (第一作者)

    new · southern med univ

  • L

    Luo, Jian

查看全部 18 位作者收起作者
  • L

    Liao, Hui

    new · southern med univ

  • Z

    Zheng, Fengxin

    new · southern med univ

  • C

    Chen, Xinhua

    new · southern med univ

  • L

    Luo, Jiajun

  • C

    Chen, Yongjun

    new · southern med univ

  • Z

    Zhao, Kunlu

    new · southern med univ

  • Z

    Zhang, Shuqin

    southern med univ

  • T

    Tian, Jinhong

    new · southern med univ

  • W

    Wu, Ting

    new · southern med univ

  • L

    Li, Yongmei

    new · southern med univ

  • L

    Li, Lu

    new · southern med univ

  • Y

    Yang, Yang

    new · southern med univ

  • L

    Lin, Cuiting

    new · southern med univ

  • Z

    Zhang, Qun (通讯)

    southern med univ

  • T

    Tian, Yuanxin (通讯)

    new · southern med univ

  • P

    Pang, Jianxin (通讯)

    new · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417